China Pb Ratio vs Free Cash Flow Yield Analysis

CPHI Stock

USD 0.20 0.01 4.76%

China Pharma financial indicator trend analysis is way more than just evaluating China Pharma Holdings prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether China Pharma Holdings is a good investment. Please check the relationship between China Pharma Pb Ratio and its Free Cash Flow Yield accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in China Pharma Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.

Pb Ratio vs Free Cash Flow Yield

Pb Ratio vs Free Cash Flow Yield Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of China Pharma Holdings Pb Ratio account and Free Cash Flow Yield. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between China Pharma's Pb Ratio and Free Cash Flow Yield is -0.1. Overlapping area represents the amount of variation of Pb Ratio that can explain the historical movement of Free Cash Flow Yield in the same time period over historical financial statements of China Pharma Holdings, assuming nothing else is changed. The correlation between historical values of China Pharma's Pb Ratio and Free Cash Flow Yield is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Pb Ratio of China Pharma Holdings are associated (or correlated) with its Free Cash Flow Yield. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow Yield has no effect on the direction of Pb Ratio i.e., China Pharma's Pb Ratio and Free Cash Flow Yield go up and down completely randomly.

Correlation Coefficient

-0.1

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Pb Ratio

Free Cash Flow Yield

A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.

Most indicators from China Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into China Pharma Holdings current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in China Pharma Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.

As of now, China Pharma's Enterprise Value Over EBITDA is increasing as compared to previous years. The China Pharma's current Enterprise Value Multiple is estimated to increase to 654.35, while Selling General Administrative is projected to decrease to under 1.4 M.

China Pharma fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock	Current Deferred Revenue	Non Currrent Assets Other	Inventory	Other Current Assets
Total Assets		0.4	0.49	0.67	1.0	0.41	0.18	0.97	0.8	0.72	0.84	0.72	0.89	0.24	0.32	0.37	0.1	0.62	-0.21	0.93	0.12	0.28	0.93	-0.62	0.91	0.69
Short Long Term Debt Total	0.4		0.0	0.51	0.32	0.9	0.95	0.24	0.35	0.77	0.72	0.77	0.01	0.39	0.49	0.92	0.28	0.93	0.59	0.11	0.54	0.4	0.39	0.34	0.05	0.59
Other Current Liab	0.49	0.0		0.54	0.48	0.3	-0.04	0.45	0.53	0.08	0.46	0.08	0.41	0.43	0.51	0.07	0.26	0.35	-0.38	0.42	-0.17	0.41	0.45	-0.43	0.42	0.03
Total Current Liabilities	0.67	0.51	0.54		0.63	0.46	0.35	0.52	0.67	0.65	0.6	0.65	0.55	0.7	0.86	0.26	0.56	0.73	0.2	0.6	0.67	0.71	0.68	-0.42	0.52	0.33
Total Stockholder Equity	1.0	0.32	0.48	0.63		0.33	0.09	0.98	0.79	0.68	0.8	0.68	0.92	0.19	0.26	0.29	0.07	0.55	-0.26	0.95	0.07	0.23	0.92	-0.67	0.94	0.67
Property Plant And Equipment Net	0.41	0.9	0.3	0.46	0.33		0.91	0.26	0.42	0.57	0.8	0.57	-0.03	0.37	0.46	0.93	0.21	0.91	0.37	0.08	0.25	0.33	0.41	0.35	0.03	0.58
Net Debt	0.18	0.95	-0.04	0.35	0.09	0.91		0.02	0.15	0.53	0.6	0.53	-0.24	0.35	0.44	0.9	0.26	0.83	0.59	-0.14	0.47	0.39	0.22	0.55	-0.2	0.49
Retained Earnings	0.97	0.24	0.45	0.52	0.98	0.26	0.02		0.75	0.61	0.76	0.61	0.91	0.03	0.11	0.25	-0.1	0.45	-0.4	0.94	-0.03	0.18	0.9	-0.68	0.95	0.67
Accounts Payable	0.8	0.35	0.53	0.67	0.79	0.42	0.15	0.75		0.64	0.76	0.64	0.64	0.33	0.39	0.35	0.18	0.61	-0.11	0.69	0.08	0.19	0.66	-0.51	0.66	0.47
Cash	0.72	0.77	0.08	0.65	0.68	0.57	0.53	0.61	0.64		0.73	1.0	0.51	0.34	0.43	0.65	0.23	0.81	0.36	0.59	0.5	0.29	0.61	-0.21	0.53	0.61
Non Current Assets Total	0.84	0.72	0.46	0.6	0.8	0.8	0.6	0.76	0.76	0.73		0.73	0.5	0.29	0.38	0.76	0.14	0.86	0.02	0.58	0.13	0.33	0.75	-0.18	0.56	0.73
Cash And Short Term Investments	0.72	0.77	0.08	0.65	0.68	0.57	0.53	0.61	0.64	1.0	0.73		0.51	0.34	0.43	0.65	0.23	0.81	0.36	0.59	0.5	0.29	0.61	-0.21	0.53	0.61
Net Receivables	0.89	0.01	0.41	0.55	0.92	-0.03	-0.24	0.91	0.64	0.51	0.5	0.51		0.12	0.17	-0.06	0.03	0.25	-0.38	0.99	0.05	0.16	0.85	-0.82	0.99	0.47
Common Stock Total Equity	0.24	0.39	0.43	0.7	0.19	0.37	0.35	0.03	0.33	0.34	0.29	0.34	0.12		0.89	0.23	0.96	0.54	0.52	0.16	0.51	0.49	0.24	-0.07	0.08	-0.05
Common Stock Shares Outstanding	0.32	0.49	0.51	0.86	0.26	0.46	0.44	0.11	0.39	0.43	0.38	0.43	0.17	0.89		0.28	0.78	0.66	0.47	0.22	0.66	0.75	0.33	-0.1	0.13	0.01
Non Current Liabilities Total	0.37	0.92	0.07	0.26	0.29	0.93	0.9	0.25	0.35	0.65	0.76	0.65	-0.06	0.23	0.28		0.12	0.85	0.44	0.04	0.16	0.16	0.31	0.43	0.0	0.6
Other Stockholder Equity	0.1	0.28	0.26	0.56	0.07	0.21	0.26	-0.1	0.18	0.23	0.14	0.23	0.03	0.96	0.78	0.12		0.39	0.59	0.06	0.49	0.4	0.11	-0.02	-0.02	-0.12
Total Liab	0.62	0.93	0.35	0.73	0.55	0.91	0.83	0.45	0.61	0.81	0.86	0.81	0.25	0.54	0.66	0.85	0.39		0.42	0.35	0.48	0.5	0.59	0.07	0.28	0.6
Property Plant And Equipment Gross	-0.21	0.59	-0.38	0.2	-0.26	0.37	0.59	-0.4	-0.11	0.36	0.02	0.36	-0.38	0.52	0.47	0.44	0.59	0.42		-0.33	0.57	0.13	-0.2	0.5	-0.4	0.04
Total Current Assets	0.93	0.11	0.42	0.6	0.95	0.08	-0.14	0.94	0.69	0.59	0.58	0.59	0.99	0.16	0.22	0.04	0.06	0.35	-0.33		0.09	0.19	0.89	-0.8	0.99	0.54
Short Term Debt	0.12	0.54	-0.17	0.67	0.07	0.25	0.47	-0.03	0.08	0.5	0.13	0.5	0.05	0.51	0.66	0.16	0.49	0.48	0.57	0.09		0.65	0.21	0.02	0.02	0.12
Common Stock	0.28	0.4	0.41	0.71	0.23	0.33	0.39	0.18	0.19	0.29	0.33	0.29	0.16	0.49	0.75	0.16	0.4	0.5	0.13	0.19	0.65		0.36	-0.1	0.14	0.09
Current Deferred Revenue	0.93	0.39	0.45	0.68	0.92	0.41	0.22	0.9	0.66	0.61	0.75	0.61	0.85	0.24	0.33	0.31	0.11	0.59	-0.2	0.89	0.21	0.36		-0.53	0.86	0.75
Non Currrent Assets Other	-0.62	0.34	-0.43	-0.42	-0.67	0.35	0.55	-0.68	-0.51	-0.21	-0.18	-0.21	-0.82	-0.07	-0.1	0.43	-0.02	0.07	0.5	-0.8	0.02	-0.1	-0.53		-0.84	-0.15
Inventory	0.91	0.05	0.42	0.52	0.94	0.03	-0.2	0.95	0.66	0.53	0.56	0.53	0.99	0.08	0.13	0.0	-0.02	0.28	-0.4	0.99	0.02	0.14	0.86	-0.84		0.55
Other Current Assets	0.69	0.59	0.03	0.33	0.67	0.58	0.49	0.67	0.47	0.61	0.73	0.61	0.47	-0.05	0.01	0.6	-0.12	0.6	0.04	0.54	0.12	0.09	0.75	-0.15	0.55

Click cells to compare fundamentals

China Pharma Account Relationship Matchups

China Pharma fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	22.2M	21.1M	22.6M	17.8M	16.5M	15.6M
Short Long Term Debt Total	4.6M	7.4M	12.5M	8.8M	4.6M	7.4M
Other Current Liab	5.8M	2.9M	1.3M	1.7M	1.6M	1.6M
Total Current Liabilities	10.0M	11.4M	10.5M	12.7M	6.8M	9.2M
Total Stockholder Equity	9.2M	8.0M	6.0M	4.3M	7.5M	7.1M
Property Plant And Equipment Net	16.0M	15.2M	13.0M	9.6M	6.8M	13.2M
Net Debt	3.5M	6.5M	7.6M	6.7M	3.2M	4.3M
Retained Earnings	(26.0M)	(28.8M)	(32.2M)	(36.2M)	(39.3M)	(37.3M)
Accounts Payable	1.4M	1.2M	926.7K	667.1K	966.4K	1.7M
Cash	1.1M	957.7K	4.9M	2.0M	1.4M	2.8M
Non Current Assets Total	16.7M	15.8M	13.6M	11.8M	10.5M	9.9M
Cash And Short Term Investments	1.1M	957.7K	4.9M	2.0M	1.4M	2.8M
Net Receivables	727.8K	583.3K	835.4K	464.5K	662.4K	629.3K
Liabilities And Stockholders Equity	22.2M	21.1M	22.6M	17.8M	16.5M	15.6M
Non Current Liabilities Total	3.0M	1.7M	6.1M	754.7K	2.2M	3.5M
Total Liab	13.0M	13.1M	16.6M	13.5M	9.0M	12.7M
Property Plant And Equipment Gross	16.0M	15.2M	41.1M	38.0M	37.2M	39.1M
Total Current Assets	5.6M	5.3M	9.1M	6.0M	6.0M	5.7M
Accumulated Other Comprehensive Income	11.6M	12.3M	12.6M	11.6M	11.5M	9.9M
Short Term Debt	2.4M	6.5M	7.2M	8.8M	3.2M	4.4M
Current Deferred Revenue	505.4K	719.8K	210.0K	520.3K	90.5K	86.0K
Non Currrent Assets Other	(16.7M)	(15.8M)	(13.6M)	(11.8M)	(397.7K)	(417.6K)
Inventory	3.6M	3.7M	3.3M	2.9M	3.7M	3.5M
Other Current Assets	187.4K	75.9K	59.3K	522.3K	178.2K	169.3K
Intangible Assets	609.4K	613.8K	589.6K	2.2M	3.7M	3.4M
Other Liab	764.4K	753.4K	805.6K	824.4K	948.1K	718.4K
Property Plant Equipment	19.3M	16.3M	15.6M	13.4M	15.4M	17.9M
Net Tangible Assets	29.9M	9.0M	7.8M	5.9M	5.3M	5.0M
Long Term Debt	2.2M	904.2K	5.3M	1.4M	1.3M	2.5M
Retained Earnings Total Equity	5.5M	(5.3M)	(26.0M)	(28.8M)	(26.0M)	(24.7M)
Short Term Investments	45.8K	53.7K	91.4K	13.8K	65.9K	80.7K
Deferred Long Term Liab	738.2K	764.4K	753.4K	805.6K	926.4K	788.0K
Short Long Term Debt	2.3M	6.5M	7.1M	8.7M	3.1M	4.3M

Currently Active Assets on Macroaxis

C	Citigroup
GM	General Motors
F	Ford Motor
GM	General Motors
V	Visa Class A

When determining whether China Pharma Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of China Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of China Pharma Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on China Pharma Holdings Stock:

How To Invest In China

Details

Is China Stock a good investment?

Details

What is China Pharma's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in China Pharma Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.

You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of China Pharma. If investors know China will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about China Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.69)

Revenue Per Share

0.63

Quarterly Revenue Growth

(0.16)

Return On Assets

(0.18)

Return On Equity

(0.75)

The market value of China Pharma Holdings is measured differently than its book value, which is the value of China that is recorded on the company's balance sheet. Investors also form their own opinion of China Pharma's value that differs from its market value or its book value, called intrinsic value, which is China Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because China Pharma's market value can be influenced by many factors that don't directly affect China Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between China Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if China Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, China Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

China Pb Ratio vs Free Cash Flow Yield Analysis

Pb Ratio vs Free Cash Flow Yield

Pb Ratio vs Free Cash Flow Yield Correlation Analysis

Correlation Coefficient

Pb Ratio

Free Cash Flow Yield

China Pharma fundamental ratios Correlations

China Pharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

China Pharma fundamental ratios Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 0.99	Net Receivables
Inventory	+ 0.99	Net Receivables
Inventory	+ 0.99	Total Current Assets
Retained Earnings	+ 0.98	Total Stockholder Equity

Inventory	- 0.84	Non Currrent Assets Other
Non Currrent Assets Other	- 0.82	Net Receivables
Non Currrent Assets Other	- 0.8	Total Current Assets
Non Currrent Assets Other	- 0.68	Retained Earnings
Non Currrent Assets Other	- 0.67	Total Stockholder Equity
Non Currrent Assets Other	- 0.62	Total Assets